

# PRIOR AUTHORIZATION CRITERIA

## BRAND NAME (generic)

**NAMENDA  
(memantine hydrochloride)**

**Prior Authorization applies only to patients less than 30 years of age.**

**Status: CVS Caremark® Criteria**

**Type: Initial Prior Authorization with Age Edit**

## POLICY

### FDA-APPROVED INDICATIONS

Namenda, Namenda XR, and memantine hydrochloride oral solution are indicated for the treatment of moderate to severe dementia of the Alzheimer's type.

### Compendial Uses

Vascular Dementia<sup>5-7</sup>

### COVERAGE CRITERIA

The requested drug will be covered with prior authorization for patients less than 30 years of age when the following criteria are met:

- The patient has any of the following diagnoses: A) Moderate to severe dementia of the Alzheimer's type, B) Vascular dementia
- AND**
- If the request is for continuation of therapy, the medication continues to provide benefit to the patient [Note: If slowing decline of cognitive function is no longer a goal, or if the patient is rapidly declining, treatment with the medication is no longer appropriate.]
- OR**
- If the request is NOT for continuation of therapy, the diagnosis is supported by a validated cognitive assessment within the past 12 months

Duration of Approval (DOA):

- 511-B: DOA: 12 months

### REFERENCES

1. Namenda [package insert]. Madison, NJ: Allergan USA, Inc.; November 2018.
2. Namenda XR [package insert]. Madison, NJ: Allergan USA, Inc.; November 2019.
3. Memantine Hydrochloride Oral Solution [package insert]. Wall, NJ: Seton Pharmaceuticals; June 2021.
4. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed May 08, 2023.
5. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 05/08/2023).
6. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and Safety of Memantine in Patients with Mild to Moderate Vascular Dementia. *Stroke*. 2002;33:1834-39.
7. Wilcock G, Mobius HJ, Stoffler A. A Double-Blind, Placebo-Controlled Multicentre Study of Memantine in Mild to Moderate Vascular Dementia. *Int Clin Psychopharmacol*. 2002;17:297-305.

Namenda PA with Age Policy 511-B UDR 06-2023

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

8. Rabins P, Blacker D, Rovner B, et al. Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias, Second Edition. *Am J Psychiatry*. 2007;164(12S):1-56.
9. Rabins P, Rovner B, Rummans T, et al. Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias. 2014;1-26.
10. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.
11. Qaseem A, Snow V, Cross T, et al. Current Pharmacological Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. *Ann Intern Med*. 2008;148:370-78.
12. Goldman JS, Hahn SE, Catania JW, et al. Genetic Counseling and Testing for Alzheimer Disease: Joint Practice Guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. *Genet Med*. 2011;13(6):597-605.
13. Goldman JS, Hahn SE, Catania JW, et al. Addendum: Genetic Counseling and Testing for Alzheimer Disease: Joint Practice Guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. *Genet Med*. 2019;21(10):2404.

Namenda PA with Age Policy 511-B UDR 06-2023

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423